Clinical Evidence 4

Established safety and tolerability: IT’S ON™ Commonly observed adverse reactions (incidence ≥5% and at least twice the rate of placebo) were extrapyramidal disorder, application site reaction, and weight gain1 SECUADO® had a discontinuation rate similar to placebo1 A total of 4.9% of patients treated with SECUADO 3.8 mg/24 hours, 7.8% of patients treated with SECUADO […]

Clinical Evidence 3

Other clinical data Sublingual asenapine • The efficacy of SECUADO® was established, in part, on data from trials with the sublingual formulation of asenapine1 Maintenance of efficacy with sublingual asenapine1 Maintenance of efficacy has been demonstrated in a placebo-controlled, double-blind, multicenter, flexible dose with sublingual asenapine (5 mg or 10 mg twice daily based on […]

Clinical Evidence 2

Significant reduction in PANSS total score at week 6 (n=607)1 Both doses of SECUADO® were also statistically superior to placebo for Clinical Global Impressions – Severity (CGI-S)1 An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and/or race1 The efficacy of SECUADO® was evaluated […]

You are now leaving the SECUADO® (asenapine) transdermal system website and moving to an external website independently operated and not managed by Noven

The site you are about to enter is intended specifically for US healthcare professionals.

Click continue if you are a US healthcare professional.